


COA

Certification of Mailing  
I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being mailed or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Certificate of Correction Branch, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

DONITA KONRAD  
Name Donita Konrad Registration No (if applicable)  
Signature 7/22/2005  
Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/633,180  
Applicant(s) : Mitchell Anthony DeLong  
Filed : August 4, 2000  
U.S. Patent No. : 6,894,175 B1  
Issued : May 17, 2005  
Title : 2-Decarboxy-2-Phosphinico Prostaglandin Derivatives  
And Methods For Their Preparation And Use  
TC/A.U. : 1626  
Examiner : Deborah C. Lambkin  
Conf. No. : 2275  
Docket No. : 8191  
Customer No. : 27752

REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 C.F.R. 1.322

ATTN: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Certificate  
JUL 29 2005  
of Correction

Dear Sir:

It is requested that the attached Certificate of Correction be issued under 37 CFR 1.322 for the above-identified patent. The mistakes are apparently due to Patent Office printing errors.

Front page of patent

Under "Related U.S. Application Data", please add -- Provisional application No. 60/148,042, filed on August 4, 1999 - -. The two provisional applications to which the above-referenced application claims priority are listed on the Declaration as filed in this case, a copy of which is attached.

Column 5

Line 47, please delete "hepateprotective" and insert therefor -- hepatoprotective --. The correct version appears at line 23 on page 7 of the specification as filed.

AUG 01 2005

Column 8

Line 14, please delete “C” and insert therefor -- C<sub>1</sub> --. The correct version appears at line 21 on page 11 of the specification as filed.

Column 11

Line 50, please delete “0.4” and insert therefor -- 4 --. The correct version appears at line 31 on page 16 of the specification as filed.

Column 13

Line 33, please delete “R<sup>9</sup>” and insert therefor -- R<sup>8</sup> --. The correct version appears at line 13 on page 19 of the specification as filed.

Column 20

Line 56, please delete “aillantoin” and insert therefor -- allantoin --. The correct version appears at line 30 on page 28 of the specification as filed.

Column 22

Lines 52-53, please delete “www.unipr.it/arpaldipfarm/erasmus/erasm14.html” and insert therefor -- www.arpa/dipfarm/erasmus/erasm14.html --. The correct version appears at line 28 on page 31 of the specification as filed.

Column 23

Line 1, please delete “Bioavailability” and insert therefor -- Bioavailability--. The correct version appears at line 8 on page 32 of the specification as filed.

Column 28

Line 52, please delete “adminstered” and insert therefor -- administered --. The correct version appears at line 18 on page 39 of the specification as filed.

Column 46

Line 3, please delete “tert-butyidimethylsilylate” and insert therefor -- tert-butyldimethylsilylate --. The correct version appears at line 6 on page 56 of the specification as filed.

Line 17, please delete “limes” and insert therefor -- times --. The correct version appears at line 19 on page 56 of the specification as filed.

Column 49

Line 53, please delete “[2.2.11]” and insert therefor -- [2.2.1]--. The correct version appears at line 8 on page 58 of the specification as filed.

Column 50

Line 67, please delete “I-nor-primary” and insert therefor -- 1-nor-primary --. The correct version appears at line 12 on page 59 of the specification as filed.

Column 53

Line 55, please delete “(NaBH)” and insert therefor -- (NaBH<sub>4</sub>) --. The correct version appears at line 11 on page 62 of the specification as filed.

Column 55

Line 5, please delete “limes” and insert therefor -- times --. The correct version appears at line 23 on page 63 of the specification as filed.

Column 59

Line 7, please delete “tert-butyldimethylsilylate” and insert therefor -- tert-butyldimethylsilylate --. The correct version appears at line 7 on page 66 of the specification as filed.

Column 61

Line 35, please delete “butyldimethylsilylate” and insert therefor -- butyldimethylsilylate --. The correct version appears at line 11 on page 69 of the specification as filed.

Column 65

Line 34, please delete “I-nor-primary” and insert therefor -- 1-nor-primary --. The correct version appears at line 14 on page 71 of the specification as filed.

Column 70

Line 46, please delete “11,3” and insert therefor -- 1,3 --. The correct version appears at line 2 on page 76 of the specification as filed.

Column 71

Line 32, please delete “I-nor-primary” and insert therefor -- 1-nor-primary --. The correct version appears at line 5 on page 77 of the specification as filed.

Column 76

Line 30, please delete "Luzernerstrasse" and insert therefor -- Lucernerstrasse --.  
The correct version appears at line 16 on page 82 of the specification as filed.

Column 84


Line 12, please delete "R<sup>7</sup>" and insert therefor -- R<sup>8</sup> --. The correct version appears in Claim 14 (which is renumbered as Claim 13 in the issued patent) of Applicant's amendment dated 16 September 2004 (copy of page enclosed).

Correction of these mistakes is believed necessary to avoid ambiguity with respect to the patentees' disclosure and claims.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY

By

  
Signature

Frank Taffy

Typed or Printed Name

Registration No. 52,270  
(513) 634-9315

22 May, 2005  
Customer No. 27752

AUG 01 2005

Claim 6. (Previously presented) The compound of claim 2, wherein  $R^1$  is a hydrogen atom.

Claim 7. (Previously presented) The compound of claim 1, wherein  $R^2$  is a hydrogen atom.

Claim 8. (Previously presented) The compound of claim 1, wherein  $R^3$  is an oxygen atom.

Claim 9. (Previously presented) The compound of claim 1, wherein  $R^4$  is an oxygen atom.

Claim 10. (Previously presented) The compound of claim 1, wherein  $R^5$  is a hydrocarbon group having 1 to 5 carbon atoms in its chain.

Claim 11. (Previously Presented) The compound of claim 10, wherein  $R^5$  has a *cis* double bond at position  $C_5-C_6$ .

Claim 12. (Canceled)

Claim 13. (Previously presented) The compound of claim 1, wherein  $R^7$  is selected from the group consisting of  $-CH_2O-$ ,  $-CH=CH-$ ,  $-CH=C=CH-$ ,  $-CH_2S-$ ,  $-CH_2CH_2-$ ,  $-CH_2NH-$ ,  $-CH_2NCH_2-$ , and  $-CH_2O(CH_2)_3O-$ .

Claim 14. (Previously presented) The compound of claim 1, wherein  $R^8$  is selected from the group consisting of a methyl group, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups.

Claim 15. (Canceled)

Claim 16. (Previously presented) The compound of claim 1, wherein bond a is selected from the group consisting of a single bond and a *cis* double bond

Claims 17-27 (Cancelled).

## DECLARATION COMBINED WITH POWER OF ATTORNEY

Attorney Docket No. 8191

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled : **2-DECARBOXY-2-PHOSPHINICO PROSTAGLANDIN DERIVATIVES AND METHODS FOR THEIR PREPARATION AND USE**, the specification of which

(check one)

☐  
☒

is attached hereto.

was filed on August 4, 2000as United States Application No. or PCT International Application Serial No. 09/633,180

and was amended on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56.

I hereby claim foreign priority benefits under Title 35 United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) Priority Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐  
Yes☐  
No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

60/158,63710/08/9960/148,04208/04/99

Application Serial No.

Filing Date

Application Serial No.

Filing Date

I hereby claim the benefit under Title 35 United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35 United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (If applicable)

As named inventor, I hereby appoint the registered practitioners associated with customer number 27752 to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO: Customer Number 27752

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor: Mitchell Anthony DeLong

Inventor's signature

Oct. 5, 2001  
DateResidence: 8084 Tyler's Circle, West Chester, Oh 45069Citizenship: USPost Office Address: 8084 Tyler's Circle, West Chester, Oh 45069

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO. : 6,894,175 B1

Page 1 of 3

APPLICATION No.: 09/633,180

DATED : May 17, 2005

INVENTOR(S) : Mitchell Anthony DeLong

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Front page of patent

Under "Related U.S. Application Data", please add -- Provisional application No. 60/148,042, filed on August 4, 1999 - -.

Column 5

Line 47, please delete "hepateprotective" and insert therefor -- hepatoprotective --.

Column 8

Line 14, please delete "C" and insert therefor -- C<sub>1</sub> --.

Column 11

Line 50, please delete "0.4" and insert therefor -- 4 --.

Column 13

Line 33, please delete "R<sup>9</sup>" and insert therefor -- R<sup>8</sup> --.

Column 20

Line 56, please delete "aillantoin" and insert therefor -- allantoin --.

Column 22

Lines 52-53, please delete "www.unipr.it/arpaldipfarm/erasmus/erasm14.html" and insert therefor -- www.arpa/dipfarm/erasmus/erasm14.html --.

Column 23

Line 1, please delete "Bloavailability" and insert therefor -- Bioavailability--.

## MAILING ADDRESS OF SENDER:

The Procter & Gamble Company  
Intellectual Property Division  
Winton Hill Business Center – Box 161  
6110 Center Hill Avenue  
Cincinnati, OH 45224

PATENT NO. 6,894,175 B1

FORM PTO 1050 (REV. 04-05)

P&amp;G Case: 8191

Send to: Attention: Certificate of Corrections Branch, Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450

No. of add'l. copies



@ 30¢ per page

AUG 01 2005

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO. : 6,894,175 B1

Page 2 of 3

APPLICATION No.: 09/633,180

DATED : May 17, 2005

INVENTOR(S) : Mitchell Anthony DeLong

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 28

Line 52, please delete "adminstered" and insert therefor -- administered --.

Column 46

Line 3, please delete "tert-butyidimethylsilylate" and insert therefor -- tert-butyldimethylsilylate --.

Line 17, please delete "limes" and insert therefor -- times --.

Column 49

Line 53, please delete "[2.2.11]" and insert therefor -- [2.2.1]--.

Column 50

Line 67, please delete "I-nor-primary" and insert therefor -- 1-nor-primary --.

Column 53Line 55, please delete "(NaBH)" and insert therefor -- (NaBH<sub>4</sub>) --.Column 55

Line 5, please delete "limes" and insert therefor -- times --.

Column 59

Line 7, please delete "tert-butyidimethylsilylate" and insert therefor -- tert-butyldimethylsilylate --.

## MAILING ADDRESS OF SENDER:

The Procter & Gamble Company  
Intellectual Property Division  
Winton Hill Business Center – Box 161  
6110 Center Hill Avenue  
Cincinnati, OH 45224

PATENT NO. 6,894,175 B1

FORM PTO 1050 (REV. 04-05)

P&amp;G Case: 8191

Send to: Attention: Certificate of Corrections Branch, Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450

No. of add'l. copies



@ 30¢ per page

AUG 01 2005



**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,894,175 B1

Page 3 of 3

APPLICATION No.: 09/633,180

DATED : May 17, 2005

INVENTOR(S) : Mitchell Anthony DeLong

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 61

Line 35, please delete "butydimethylsilylate" and insert therefor -- butyldimethylsilylate --

Column 65

Line 34, please delete "I-nor-primary" and insert therefor -- 1-nor-primary --.

Column 70

Line 46, please delete "11,3" and insert therefor -- 1,3 --.

Column 71

Line 32, please delete "I-nor-primary" and insert therefor -- 1-nor-primary --.

Column 76

Line 30, please delete "Luzernerstrasse" and insert therefor -- Lucernerstrasse --.

Column 84

Line 12, please delete "R<sup>7</sup>" and insert therefor -- R<sup>8</sup> --.

MAILING ADDRESS OF SENDER:

The Procter & Gamble Company  
Intellectual Property Division  
Winton Hill Business Center -- Box 161  
6110 Center Hill Avenue  
Cincinnati, OH 45224

PATENT NO. 6,894,175 B1

FORM PTO 1050 (REV. 04-05)

P&G Case: 8191

Send to: Attention: Certificate of Corrections Branch, Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450

No. of add'l. copies



@ 30¢ per page

AUG 01 2005